Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: Lane3 who wrote (96743)	1/25/2005 2:35:41 PM
From: Ilaine	Respond to of 793698

Given that BiDil is a novel combination of two old drugs whose patents have long expired, this is a way to get more life out of expired patents. It may be more than that, but given the eagerness of drug companies to figure out ways to keep their patents going, I am cynical. I am taking a generic drug for an off-label purpose -- because if I take it for the on-label purpose, it's not a generic anymore. Generic = $7, non-generic > $100. Caveat emptor.

To: Lane3 who wrote (96743)	1/25/2005 2:41:01 PM
From: Ilaine	Read Replies (1) \| Respond to of 793698

Funny article comparing BiDil to Goober Grape, you know, the stuff that combined peanut butter and grape jelly in the same jar. Apparently the major drug companies don't want to sell it so Nitromed plans to market it themselves. stocklemon.com